• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Rigel Pharmaceuticals - Articles and news items

Rigel’s fostamatinib successfully meets endpoint in chronic ITP trial

Industry news / 30 August 2016 / Niamh Louise Marriott, Digital Content Producer

The study (n=76) showed that 18% of patients receiving fostamatinib achieved a stable platelet response compared to none receiving a placebo control (p=0.0261)…

 

Webinar: SIFT-MS: A New Tool for Impurity Profiling in Pharmaceutical ProductsLEARN MORE
+ +